Nuvalent’s $300M offering; Spark ends epilepsy deal; A small IPO
Nuvalent initiates $300M public offering: The cancer biotech on Monday announced a $300 million offering of its common stock. The move …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
